SuperworthArmata Pharmaceuticals revenue ARMP
Sales by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2020
- n/m
- a quarter missing
- Latest quarter, Q2 FY20
- $31K
Armata Pharmaceuticals' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY20, it was $31K.
Revenue over time
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier |
|---|---|---|---|
| Q2 FY20 | $31K | n/a | |
| Q1 FY15 | $102K | −2% | |
| Q3 FY14 | $103K | n/a | |
| Q2 FY14 | $101K | −68% | |
| Q1 FY14 | $104K | +373% | |
| Q3 FY13 | −$3K | n/a | |
| Q2 FY13 | $314K | n/a | |
| Q1 FY13 | $22K | n/a |
Against its peers
Companies in Healthcare nearest Armata Pharmaceuticals' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ARMPArmata Pharmaceuticals | n/m | |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| ICCCImmucell | $30.7M | +8% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ELMDElectromed | $73.8M | +15% a year |
| UTMDUtah Medical Products | $36.1M | −7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| INFUInfuSystem | $143.3M | +2% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| Peer median | $79.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Armata Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.